Praxis Precision Medicines, Inc. (PRAX)
PRAX moved a median of -0.45% 30 minutes after news, and -0.78% by the close. How PRAX actually reacts to news — the realized, point-in-time move the market made, measured across 430 labeled events over the last three years with zero look-ahead.
PRAX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 45% | 424 |
| 30-min | -0.45% | 37% | 428 |
| 60-min | -0.36% | 42% | 428 |
| to close | -0.78% | 43% | 424 |
| Middle 50% of PRAX reactions | -1.67% to +0.64% |
|---|---|
| Median reaction (30-min) | -0.45% |
| Measured reactions | 430 |
Half of all Praxis Precision Medicines, Inc. news events land between -1.67% and +0.64% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How PRAX reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 41 | -0.12% | 42% | -0.87% |
| Rating reiterations | 171 | -0.14% | 43% | 0.00% |
| Price-target raises | 26 | -0.02% | 50% | -0.22% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how PRAX ranks against every other measured name →
That’s how PRAX usually reacts — get an email when it moves on news →Email me when PRAX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to PRAX's baseline. Nothing else.
Recent PRAX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -1.10% | -5.20% | |
| Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.06% | -0.33% | |
| Form 10-Q Praxis Precision Medicin For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +3.69% | +5.62% | |
| Form 8-K Praxis Precision Medicin For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | +3.69% | +5.62% | |
| Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results | Press release | GlobeNewswire | +3.69% | +5.62% | |
| Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.95% | +1.34% | |
| Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026 | Press release | GlobeNewswire | -1.92% | -0.29% | |
| Form 8-K Praxis Precision Medicin For: Jul 07 | SEC filing · Form 8-K | SEC EDGAR | +0.11% | +2.94% | |
| Praxis Precision Medicines and Remagine Labs Announce Strategic Collaboration to Develop Transdermal Ulixacaltamide for Essential Tremor | Press release | GlobeNewswire | -0.92% | +2.81% | |
| Form 8-K Praxis Precision Medicin For: Jun 29 | SEC filing · Form 8-K | SEC EDGAR | +0.45% | -1.74% | |
| Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.45% | -1.74% | |
| Form 8-K Praxis Precision Medicin For: Jun 29 | SEC filing · Form 8-K | SEC EDGAR | -3.87% | -1.80% | |
| Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | Press release | GlobeNewswire | -3.87% | -1.80% | |
| Form 8-K Praxis Precision Medicin For: Jun 22 | SEC filing · Form 8-K | SEC EDGAR | +1.67% | +2.30% | |
| Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants | Press release | GlobeNewswire | +1.63% | +3.70% | |
| Form 8-K Praxis Precision Medicin For: Jun 10 | SEC filing · Form 8-K | SEC EDGAR | +0.92% | -2.35% | |
| Praxis Precision Medicines to Participate in Goldmans Sachs 47th Annual Global Healthcare Conference | Press release | GlobeNewswire | +2.27% | -3.85% | |
| Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +2.57% | +7.62% | |
| Form 8-K Praxis Precision Medicin For: Jun 01 | SEC filing · Form 8-K | SEC EDGAR | +0.56% | -15.94% | |
| Praxis Precision Medicines Provides Vormatrigine Program Update | Press release | GlobeNewswire | +0.56% | -15.94% | |
| Form 8-K Praxis Precision Medicin For: May 07 | SEC filing · Form 8-K | SEC EDGAR | +0.12% | -0.51% | |
| Form 10-Q Praxis Precision Medicin For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -3.63% | -4.50% | |
| Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results | Press release | GlobeNewswire | -3.63% | -4.50% | |
| Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.14% | +0.85% | |
| Praxis Precision Medicines to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026, and Participate in Upcoming Investor Conference | Press release | GlobeNewswire | -0.01% | -1.94% | |
| Form DEF 14A Praxis Precision Medicin For: Jun 10 | SEC filing · Form DEF | SEC EDGAR | -1.45% | +2.37% | |
| Form DEFA14A Praxis Precision Medicin | SEC filing · Form DEFA14A | SEC EDGAR | -1.45% | +2.37% | |
| Form 8-K Praxis Precision Medicin For: Apr 14 | SEC filing · Form 8-K | SEC EDGAR | +0.35% | -2.33% | |
| Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor | Press release | GlobeNewswire | +7.38% | +5.42% | |
| Praxis to Showcase Essential3, the First Positive Phase 3 Program in Essential Tremor, at AAN 2026 | Press release | GlobeNewswire | +0.28% | -0.94% | |
| Form 8-K Praxis Precision Medicin For: Apr 06 | SEC filing · Form 8-K | SEC EDGAR | -1.66% | -0.88% | |
| Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy | Press release | GlobeNewswire | +1.02% | -2.71% | |
| Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +1.02% | -2.71% | |
| Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs | Press release | GlobeNewswire | +3.62% | +11.41% | |
| Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.92% | -2.66% | |
| Form 10-K Praxis Precision Medicin For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -5.00% | +5.27% | |
| Form 8-K Praxis Precision Medicin For: Feb 19 | SEC filing · Form 8-K | SEC EDGAR | -5.00% | +5.27% | |
| Form S-8 Praxis Precision Medicin | SEC filing · Form S-8 | SEC EDGAR | -5.00% | +5.27% | |
| Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results | Press release | GlobeNewswire | -5.00% | +5.27% | |
| Form 8-K/A Praxis Precision Medicin For: Feb 06 | SEC filing · Form 8-K | SEC EDGAR | -0.69% | +0.45% | |
| Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | -1.48% | -1.51% | |
| Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.10% | +1.36% | |
| Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy | Press release | GlobeNewswire | -0.50% | +5.48% | |
| Praxis Precision Medicines Enters Its Next Chapter Following a Pivotal Year of Progress | Press release | GlobeNewswire | -2.16% | -2.56% | |
| Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -2.16% | -2.56% | |
| Form 8-K Praxis Precision Medicin For: Jan 08 | SEC filing · Form 8-K | SEC EDGAR | +1.65% | -1.20% | |
| Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments | Press release | GlobeNewswire | +1.65% | -1.20% | |
| Form 8-K Praxis Precision Medicin For: Jan 06 | SEC filing · Form 8-K | SEC EDGAR | +2.08% | +3.21% | |
| Form 8-K Praxis Precision Medicin For: Jan 06 | SEC filing · Form 8-K | SEC EDGAR | +4.31% | +6.50% | |
| Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering | Press release | GlobeNewswire | +4.31% | +6.50% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the PRAX section they belong to.
Where else PRAX is measured.
PRAX earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Praxis Precision Medicines, Inc.'s median reaction calculated?
Every labeled PRAX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 430 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 37% of PRAX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does PRAX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.